Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Frisell

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
BMC Cancer|May 28, 2017
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trialJana de Boniface, Jan Frisell, Yvette Andersson, et al.
Breast Cancer Research and Treatment|April 22, 2022
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapyJana de Boniface, Jan Frisell, Thorsten Kühn, et al.
The British Journal of Surgery|June 6, 2025
Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trialYvette Andersson, Leif Bergkvist, Lisa Rydén, et al.
Breast Cancer Research and Treatment|September 15, 2016
Long-term outcome in young women with breast cancer: a population-based studyHanna Fredholm, Kristina Magnusson, Linda S Lindström, et al.
BMC Cancer|December 1, 2017
Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profilingGovindasamy-Muralidharan Karthik, Mattias Rantalainen, Gustav Stålhammar, et al.
Scientific Reports|December 1, 2016
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkersMattias Rantalainen, Daniel Klevebring, Johan Lindberg, et al.
Journal of the National Cancer Institute|April 5, 2017
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem CellsRan Ma, Govindasamy-Muralidharan Karthik, John Lövrot, et al.
Breast (Edinburgh, Scotland)|March 13, 2022
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trialMatilda Appelgren, Helena Sackey, Yvonne Wengström, et al.
The Lancet Regional Health. Europe|October 10, 2024
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trialTove Filtenborg Tvedskov, Robert Szulkin, Sara Alkner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2026
Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMACSara Alkner, Matilda Appelgren, Robert Szulkin, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
BMC Cancer|May 28, 2017
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trialJana de Boniface, Jan Frisell, Yvette Andersson, et al.
Breast Cancer Research and Treatment|April 22, 2022
False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapyJana de Boniface, Jan Frisell, Thorsten Kühn, et al.
The British Journal of Surgery|June 6, 2025
Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trialYvette Andersson, Leif Bergkvist, Lisa Rydén, et al.
Breast Cancer Research and Treatment|September 15, 2016
Long-term outcome in young women with breast cancer: a population-based studyHanna Fredholm, Kristina Magnusson, Linda S Lindström, et al.
BMC Cancer|December 1, 2017
Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profilingGovindasamy-Muralidharan Karthik, Mattias Rantalainen, Gustav Stålhammar, et al.
Scientific Reports|December 1, 2016
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkersMattias Rantalainen, Daniel Klevebring, Johan Lindberg, et al.
Journal of the National Cancer Institute|April 5, 2017
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem CellsRan Ma, Govindasamy-Muralidharan Karthik, John Lövrot, et al.
Breast (Edinburgh, Scotland)|March 13, 2022
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trialMatilda Appelgren, Helena Sackey, Yvonne Wengström, et al.
The Lancet Regional Health. Europe|October 10, 2024
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trialTove Filtenborg Tvedskov, Robert Szulkin, Sara Alkner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 23, 2026
Association between shoulder joint radiation dose and arm morbidity in the randomized breast cancer trial SENOMACSara Alkner, Matilda Appelgren, Robert Szulkin, et al.
Pageof 5